A case of pembrolizumab-induced hemophagocytic lymphohistiocytosis successfully treated with pulse glucocorticoid therapy

Treatments using immune checkpoint inhibitors such as pembrolizumab lead to immune mediated adverse effects including hemophagocytic lymphohistiocytosis (HLH). Herein, we present a case where HLH developed after pembrolizumab administration, which was treated using high dose prednisolone. He develop...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Respir Med Case Rep
Egile Nagusiak: Takahashi, Hidenori, Koiwa, Tomohiro, Fujita, Akira, Suzuki, Takayuki, Tagashira, Amane, Iwasaki, Yoshinobu
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier 2020
Gaiak:
Case Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7260580/
https://ncbi.nlm.nih.gov/pubmed/32489850
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.rmcr.2020.101097
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak